<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588026</url>
  </required_header>
  <id_info>
    <org_study_id>AK580</org_study_id>
    <nct_id>NCT03588026</nct_id>
  </id_info>
  <brief_title>Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576</brief_title>
  <acronym>CAPSTONE</acronym>
  <official_title>Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AKARI Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AKARI Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      rVA576 for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      rVA576, a small protein complement C5 inhibitor which prevents the cleavage of C5 by C5&#xD;
      convertase into C5a and C5b, will be used in an open label, non-comparative clinical trial in&#xD;
      patients with PNH.&#xD;
&#xD;
      Patients will be treated with rVA576 by daily subcutaneous injection in order to determine&#xD;
      the safety and efficacy of the drug in these circumstances.&#xD;
&#xD;
      If satisfactory control of the PNH is achieved, and at the discretion of the Principal&#xD;
      Investigator (PI), patients will have the option of remaining on rVA576 and being entered&#xD;
      into the long term follow-up study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2018</start_date>
  <completion_date type="Actual">September 3, 2020</completion_date>
  <primary_completion_date type="Actual">September 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HB (Haemoglobin) stabilisation rate and the avoidance of packed red blood cells (PRBC) transfusions</measure>
    <time_frame>9 months</time_frame>
    <description>Haemoglobin stabilisation rate defined as haemoglobin greater than the set point for each patient during the pre-study randomisation period and the avoidance of PRBC transfusions during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of units of packed red blood cells (PRBC) transfused</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>Number of units of packed red blood cells (PRBC) transfused from Baseline Day 1 to Day 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieve transfusion avoidance</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>Percentage of patients who achieve transfusion avoidance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in (QOl) Quality of Life score</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>Change in Quality of Life score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (LDH)</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>AUC (Area under the curve) (LDH) Lactate Dehydrogenase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CH50</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>CH50 (Classical haemolytic 50% lysis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>Arm 1 - 9 months of treatment (rVA576 plus SOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - 6 months on SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months on SOC only. Followed by 3 months (SOC plus rVA576).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rVA576</intervention_name>
    <description>6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.</description>
    <arm_group_label>Arm 1 - 9 months of treatment (rVA576 plus SOC)</arm_group_label>
    <arm_group_label>Arm 2 - 6 months on SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care (SOC)</intervention_name>
    <description>6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.</description>
    <arm_group_label>Arm 1 - 9 months of treatment (rVA576 plus SOC)</arm_group_label>
    <arm_group_label>Arm 2 - 6 months on SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to give informed consent to treatment with rVA576&#xD;
&#xD;
          2. Diagnosed with paroxysmal nocturnal haemoglobinuria (PNH)&#xD;
&#xD;
          3. Have not received any complement inhibitor within the 4 months prior to screening&#xD;
&#xD;
          4. ≥ 18 years of age at the time of screening&#xD;
&#xD;
          5. Weight ≥50kg&#xD;
&#xD;
          6. Complete transfusion medical history for 12 months&#xD;
&#xD;
          7. Transfusion dependent&#xD;
&#xD;
          8. LDH ≥1.5 x the ULN&#xD;
&#xD;
          9. Willing to receive appropriate prophylaxis against Neisseria meningitidis infection,&#xD;
             by both immunisation and continuous or intermittent antibiotics&#xD;
&#xD;
         10. Willing to avoid prohibited medications such as other complement inhibitors and&#xD;
             chemotherapeutic agents&#xD;
&#xD;
         11. Patients must agree to avoid pregnancy and fathering children from the time of signing&#xD;
             the Informed Consent Form until 90 days after the last dose of rVA576.&#xD;
&#xD;
         12. Patients who are on erythropoietin and/or immunosuppressant treatment should be on&#xD;
             stable doses for at least 6 months.&#xD;
&#xD;
         13. Patients who are taking systemic corticosteroids should be on a stable dose for at&#xD;
             least 4 weeks.&#xD;
&#xD;
         14. Patients on anticoagulant therapy should be well-controlled prior to entry.&#xD;
&#xD;
         15. Patients taking iron and/or folic acid supplements should be on a stable dose for at&#xD;
             least 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients whose mean haemoglobin level over the previous 12 months prior to screening&#xD;
             was greater than 105 g/L (10.5g/dL)&#xD;
&#xD;
          2. Severe bone marrow failure&#xD;
&#xD;
          3. Patients with a platelet count of ≤ 70 x 109/L&#xD;
&#xD;
          4. Patients with known or suspected acquired somatic mutations affecting the bone marrow&#xD;
             (e.g. acute myeloid leukaemia) which may be associated with PNH&#xD;
&#xD;
          5. Chemotherapy within 3 months of screening visit&#xD;
&#xD;
          6. History of recurrent bacterial infections or suspicion of active bacterial infections&#xD;
             requiring antibiotic therapy&#xD;
&#xD;
          7. Planned or actual pregnancy or breast feeding (females)&#xD;
&#xD;
          8. Known allergy to ticks or severe reaction to arthropod venom (e.g. bee or wasp venom)&#xD;
&#xD;
          9. Unresolved N. meningitidis infection.&#xD;
&#xD;
         10. Patients who are not willing to receive adequate immunisation against N. meningitidis&#xD;
             unless, in the opinion of the investigator, the risks of delaying therapy outweigh the&#xD;
             risks of developing a meningococcal infection&#xD;
&#xD;
         11. Impaired hepatic function unless, in the opinion of the investigator, the risks of&#xD;
             delaying therapy outweigh the risks of treatment in the presence of impaired hepatic&#xD;
             function&#xD;
&#xD;
         12. Patients with a glomerular filtration rate (GFR) of &lt;30mL/min/1.73m2 unless, in the&#xD;
             opinion of the investigator, the risks of delaying therapy outweigh the risks of&#xD;
             treatment in the presence of impaired renal function&#xD;
&#xD;
         13. Participation in other clinical trials within 4 weeks of signing the consent form&#xD;
&#xD;
         14. History of active systemic autoimmune diseases.&#xD;
&#xD;
         15. Any other systemic disorders that could interfere with the evaluation of the study&#xD;
             treatment&#xD;
&#xD;
         16. Failure to comply with protocol requirements&#xD;
&#xD;
         17. Known Hepatitis B or Hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrius Degulys, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University Hospital Santaros Klinikos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almaty City Hospital No.7</name>
      <address>
        <city>Almaty</city>
        <state>Microdistrict Kalkaman</state>
        <zip>050006</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos , Santariškių St. 2, LT-08661,</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kelaniya, Faculty of Medicine, Thalagolla Road</name>
      <address>
        <city>Colombo</city>
        <zip>Ragama/11010</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
    <country>Lithuania</country>
    <country>Sri Lanka</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

